Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors - For the many or the few? Lipid-Lowering Agents ESC Premium Access ESC Congress 2018

ESC 365 is supported by

ESC 365 is supported by